Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06374797 · ClinicalTrials.gov registry record · Phase 2
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
A Phase 2 study of Acute Kidney Injury, sponsored by CalciMedica.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06374797: Active Phase 2 study of Acute Kidney Injury, sponsored by CalciMedica.
NCT06374797 is a Phase 2 study of Acute Kidney Injury that is active but no longer recruiting, run by CalciMedica. The registered enrollment target is 150 participants, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06374797, a Phase 2 study of Acute Kidney Injury, is active but no longer recruiting, sponsored by CalciMedica.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.
Primary Outcome
The primary efficacy analysis will apply the win ratio method and the Finkelstein-Schoenfeld method to the primary endpoints. The win ratio method allocates all Auxora and placebo pairs to the components that comprise the primary endpoint in a hierarchical fashion. Categories (a) and (c) represent Auxora wins based on all-cause mortality and days ventilator-free and KRT-free. Similarly, categories (b) and (d) represent placebo wins. Category (e) represents ties. (a) Death on placebo, but alive
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Auxora
Study Locations (20)
California
- UCLA - Los Angeles
- Stanford Health Care - Stanford
- Torrance Memorial Medical Center - Torrance
Massachusetts
- Brigham & Woman's Hospital - Boston
- Lahey Hospital and Medical Center - Burlington
Michigan
- Henry Ford - Detroit
- My Michigan Health - Midland
Missouri
- University of Missouri - Columbia
- Hannibal Regional - Hannibal
Alabama
- University of Alabama - Birmingham
Arizona
- Chandler Regional Hospital - Chandler
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What the registry record for NCT06374797 still lists
NCT06374797 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06374797 names 20 study sites across 15 states, led by California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT06374797 about?
NCT06374797 is a clinical study titled "A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"". Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days...
What is the current status of trial NCT06374797?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-07-01. Estimated completion is 2026-04.
What conditions does trial NCT06374797 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT06374797?
The interventions under investigation include: Placebo (DRUG), Auxora (DRUG).
Who is sponsoring clinical trial NCT06374797?
This trial is sponsored by CalciMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06374797 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06374797's enrollment target sits among peer trials
150 35th of 74 higher than 38 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI